Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

May 2024

Risk of gastrointestinal perforation in patients with rheumatic diseases exposed to janus kinase inhibitors versus adalimumab: Nationwide cohort study

Arthritis Rheumatol 2024 doi: 10.1002/art.42862 Epub ahead of print

Meyer A,

Weill A,

Crude gastrointestinal perforation (GIP) incidence rate was higher for the JAKi group compared with those receiving adalimumab, however rates of GIP did not differ between JAKi and adalimumab groups in the weighted and adjusted model. Hoisnard et al compared the risk of GIP in patients initiating treatment with JAKis or adalimumab among real-world patients with rheumatic disease.

Keywords:

Janus kinase inhibitors and tumour necrosis factor inhibitors show a favourable safety profile and similar persistence in rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: Real-world data from the BIOBADASER registry

Ann Rheum Dis 2024 doi: 10.1136/ard-2023-225271 Epub ahead of print

Results of this analysis by Hernández-Cruz, et al. show that infections, herpes zoster and gastrointestinal AEs in patients with RA tended to be more frequent with JAKi treatment versus TNFi. They also found that treatment persistence was similar with JAKi and TNFi in patients with RA and axSpA, and only slightly higher for TNFi in patients with PsA.

Keywords:

January 2024

Cardiovascular Safety of Janus Kinase Inhibitor Therapy in a Multi-ethnic Population

Musculoskeletal Care 2023 doi 10.1002/msc.1853 Epub ahead of print

Sunmboye K,

Petrie T,

Durrani M

This study by Sunmboye, et al. investigated the relationship between CV event incidence and age in a multi-ethnic population that received JAK inhibitor therapy. They concluded that JAK inhibitor therapy was generally safe in a multi-ethnic population with a large age range, but they did find a statistically significant but numerically small positive correlation between age and CV incidence

Keywords:

December 2023

Real-world Comparative Study of the Efficacy of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: The ANSWER Cohort Study

Rheumatology 2023 doi 10.1093/rheumatology/kead543

Maeda T,

Okano T,

Ueda Y,

Fujii T,

Hata K,

Yoshikawa A,

Ebina K,

Etani Y,

Amuro H,

Hara R,

Okano T,

This multicentre, retrospective study by Hayashi, et al. found no significant differences in efficacy and safety between tofacitinib, baricitinib, peficitinib and upadacitinib in patients with RA. Predictive factors for resistance to LDA achievement included baseline CRP and CDAI for tofacitinib and baseline glucocorticoid dose, baseline CDAI and number of previous b/tsDMARDs for baricitinib.

Keywords:

October 2023

Janus Kinase Inhibitor—Tofacitinib Associated with Pemphigus: An Analysis of the FDA Adverse Event Reporting System Data

ExpExpert Opin Drug Saf. 2023;22(12):1317–1320 doi: 10.1080/14740338.2023.2248872

Wang L,

Zhao B

This study presents initial data suggesting an association between the use of JAK inhibitors and pemphigus. This research used the FAERS database to investigate connections between JAK inhibitor usage and the occurrence of pemphigus as an adverse event.

Keywords:

September 2023

Cardiovascular Safety of Janus Kinase Inhibitors in Patients with Rheumatoid Arthritis: Systematic Review and Network Meta-analysis

Front Pharmacol. 2023; 8(14):1237234 doi 10.3389/fphar.2023.1237234

Wei Q,

Wang H,

Zhao J,

Luo Z,

Wang C,

Zhu C,

Su N,

Zhang S

This meta-analysis by Wei, et al. found that JAKi therapy was not associated with a higher risk of MACE than treatment with adalimumab, abatacept, or placebo. However, a higher incidence of all-cause mortality was observed with tofacitinib treatment than with adalimumab treatment.

Keywords:

Differential Properties of Janus Kinase Inhibitors in the Treatment of Immune-mediated Inflammatory Diseases

Rheumatology (Oxford) 2023;63(2):298–308 doi 10.1093/rheumatology/kead448

Choy E,

Lippe R,

JAKis differ in structure, which affects their inhibitory concentration for different JAKs.

This review by Taylor, et al. compares the pharmacological profiles of JAKis, including abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib, and upadacitinib.

Keywords:

February 2023

Opportunistic Infections Associated with Janus Kinase Inhibitor Treatment for Rheumatoid Arthritis: A Structured Literature Review

Semin Arthritis Rheum. 2023;58:152120

Desai S,

Barry J,

Strengholt S,

Galloway J

Structured literature review shows a varied incidence of opportunistic infections (OIs) among RA patients exposed to JAK inhibitors.

Keywords:

August 2022

Venous Thromboembolism Risk with Janus Kinase Inhibitors: Is it a Class Wide Effect? (Editorial)

Expert Opin Drug Saf. 2022. doi: 10.1080/14740338.2022.2100343

Jubber A,

Woodward J,

Hasan T,

Moorthy A

It is too early to conclude that the second-generation JAK inhibitors have a lower VTE risk and caution in patients with VTE risk factors is required.

Keywords:

May 2022

Safety Profile of Upadacitinib up to 3 Years in Psoriatic Arthritis: An Integrated Analysis of Two Pivotal Phase 3 Trials

Rheumatol Ther. 2022 doi: 10.1007/s40744-021-00410-z

Nash P,

Lippe R,

Liu J,

Upadacitinib 15 mg once daily demonstrated a similar safety profile to adalimumab 40 mg every other week, except for higher rates of HZ and opportunistic infections with upadacitinib treatment in patients treated for PsA